Magainin Pharmaceuticals Inc. has rearranged its technology portfolio, lessening its emphasis on its namesake magainin compounds and opportunistically adding a capability to elucidate the genetic pathways for susceptibility to disease.

The new skills have been brought to MAGN by Roy Levitt of Johns Hopkins University, who has been named executive vice president and director of MAGN's Institute of Molecular Medicine. Levitt brings with him technology to identify the genes responsible for controlling bronchial hyperresponsiveness associated with asthma.